The courier is a blockbuster!

Product

Product
Supplier
Inquiry





 My ECHEMI

 EN

The courier is a blockbuster!

 Last Update: 2022-06-05

 Source: Internet

 Author: User

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

▎WuXi AppTec Content Team Editor Today, Nkarta announced that the company's two major chimeric antigen receptor (CAR) natural killer (NK) cell candidate therapies, NKX101 and NKX019, are in two early-stage treatments for different blood cancer patient populations.
Positive results in clinical trials
.

This is the first time Nkarta has announced the clinical trial results of its CAR-NK R&D program
.

The two CAR-NK therapies not only showed good safety, but also achieved complete remission in more than half of the patients who had received multiple previous treatments
.

This result also demonstrates the broad prospects of ready-to-use NK cell therapy, which has attracted widespread attention in the industry
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

The courier is a blockbuster!

Related Articles

Courier doubles the "cancer-free survival" time of patients with early bladder cancer, and the blockbuster PD-1 inhibitor is approved by the FDA